|MDACC Study No:||2011-0784 (clinicaltrials.gov NCT No: NCT01466179)|
|Title:||An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)|
|Principal Investigator:||Hagop Kantarjian|
|Study Description:||The goal of this clinical research study is to learn if receiving blinatumomab |
can help to control relapsed or refractory B-precursor ALL. The safety of this
drug will also be studied.
Blinatumomab is designed to bind to a defensive cell (killer cell, or T-cell)
from the body's own immune system and guiding it toward the tumor cell.
Blinatumomab can then "navigates" the immune system toward the tumor cells,
which may help to destroy them.